Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)
Arch Resources(US:ARCH) Globenewswire·2025-09-17 11:15Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated in CKD, discovered in pre-clinical studies led by Dr. Justin Chun The Company has filed both composition and method of use patents relating to the CKD platform. The Arch CKD program will be led by Dr. Justin Chun, who joins the Company as a Principal Scientist CKD is largely an unmet medical need, currently a ...